clinical trial · NCT07230691
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
Janssen Research & Development, LLC·—·recruiting·n = 380
Carcinoma, Non-Small-Cell Lung
brief summary
The purpose of this study is to describe the clinical and health-related outcomes of amivantamab-containing regimens for the treatment of common epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC; most common type of lung cancer) in a real-world setting. Metastatic NSCLC is when this disease spreads to other parts of body. NSCLC may occur due to mutations (changes) in many genes including epidermal growth factor receptor (EGFR).
started
Dec 3, 2025
primary completion
Nov 19, 2030
completion
Dec 17, 2030
last updated
Jun 5, 2026
official title
Prospective, Multi Country, Observational Study of Clinical Outcomes in EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Approved Amivantamab-containing Regimens Under Standard Clinical Practice
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol